
Belantamab mafodotin–induced corneal changes in patients with multiple myeloma
Investigators from across the US and UK reported that histopathologic study of the corneal epithelium of patients with multiple myeloma who had been treated with belantamab mafodotin (Blenrep, GlaxoSmithKline), an antibody-drug conjugate (ADC), detected …